Maximize Your Impact at AD/PD 2026
AD/PD 2026 is a globally respected gathering for leaders in neuroscience, clinical research, and pharmaceutical innovation, taking place March 17–20, 2026, at Bella Center in Copenhagen, Denmark. The event brings together scientific experts, biopharma executives, investors, and healthcare decision-makers focused on Alzheimer’s and Parkinson’s diseases. For companies operating in neurodegeneration, CNS drug development, and aging research, this conference holds strategic value as a venue where clinical data is revealed, new collaborations are formed, and future investment directions are decided.
Global stakeholders use AD/PD to evaluate experimental therapies, identify data partners, and assess which vendors are reshaping the drug development pipeline. The attendee base includes principal investigators, clinical directors, heads of R&D, and C-level executives from large pharma to emerging biotech. Many attendees hold direct influence over clinical trial design, funding priorities, and technology adoption decisions. Early visibility into these attendees helps commercial and scientific teams align their outreach to active programs and strike partnerships when timelines matter most.
How Sales, Marketing and Revops Teams Can Use This Attendee List
The enriched conference attendee list from Vendelux can be used by life sciences commercial teams to effectively plan and personalize their engagement ahead of AD/PD 2026. Knowing which attendees oversee clinical development, CNS pipelines, or translational research enables go-to-market teams to segment contacts by therapeutic focus, institutional affiliation, or funding stage.
Sales representatives can prioritize introductions to executives at biopharma firms advancing neurology pipelines. Marketing teams can tailor messaging around disease-specific targets or trial endpoints. Early access to attendee data allows business development leaders to book conversations with decision-makers evaluating scientific partnerships. With the enriched attendee list in hand, companies can increase hit rates for meeting requests, improve booth traffic quality, and stay top-of-mind through timely post-conference follow-up.
Whether seeking scientific collaborators, CRO relationships, or out-licensing opportunities, this data ensures your team is not relying on serendipity but targeting the right people with relevance and precision. This is how to get more meetings and extend your influence after the event ends.
Timing Is Everything
AD/PD 2026 takes place from March 17 to March 20, 2026. Early engagement gives commercial and R&D teams an edge as many attending executives plan their meeting agendas weeks in advance. Reaching out in Q4 2025 and early Q1 2026 maximizes your chance of securing time with clinical directors, program leads, and sourcing teams.
By uploading your target account list into Vendelux, you can see which buyers and partners are attending and align outreach accordingly. Teams who start early not only improve their visibility on-site but extend their pipeline of conversations for months after the event.
What’s Included in the AD/PD 2026 Attendee List?
Vendelux provides visibility into executives expected to attend AD/PD 2026 using a combination of organizer-sourced information and audience intelligence predictions. Clients can upload their own list of strategic accounts to find matched attendees planning to be on-site.
The enriched attendee list includes first and last name, professional title, company name, company domain, city, state, and country, LinkedIn profile, verified email address, and phone number when available.
Where Is AD/PD 2026?
The conference will be held at the Bella Center in Copenhagen, Denmark.
When Is AD/PD 2026?
AD/PD 2026 runs from March 17 to March 20, 2026.
What Type of Event Is AD/PD 2026?
AD/PD 2026 is an international conference focused on Alzheimer’s and Parkinson’s disease research and drug development. The event features data presentations, keynote lectures, panel sessions, and extensive networking for professionals across academia, biotech, and pharma working in neurodegeneration.
How Many People Attend AD/PD 2026?
AD/PD 2026 is expected to draw over 4,000 attendees from more than 65 countries. The audience includes senior scientists, life sciences executives, clinical research leaders, and business development professionals.
